BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25971429)

  • 21. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
    Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
    Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
    Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
    J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.
    Lorenzo PI; Saatcioglu F
    Neoplasia; 2008 May; 10(5):418-28. PubMed ID: 18472959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.
    Ahmad R; Raina D; Joshi MD; Kawano T; Ren J; Kharbanda S; Kufe D
    Cancer Res; 2009 Sep; 69(17):7013-21. PubMed ID: 19706766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells.
    Ahmed KM; Dong S; Fan M; Li JJ
    Mol Cancer Res; 2006 Dec; 4(12):945-55. PubMed ID: 17189385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.
    Zheng F; Wu J; Zhao S; Luo Q; Tang Q; Yang L; Li L; Wu W; Hann SS
    J Exp Clin Cancer Res; 2015 May; 34(1):41. PubMed ID: 25948105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
    Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
    Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Desiniotis A; Schäfer G; Klocker H; Eder IE
    Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
    Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines.
    Katayama H; Murashima T; Saeki Y; Nishizawa Y
    Int J Oncol; 2010 Mar; 36(3):553-62. PubMed ID: 20126974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt.
    Miyazaki T; Bub JD; Iwamoto Y
    Biochim Biophys Acta; 2008 Oct; 1782(10):593-604. PubMed ID: 18718531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
    Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
    Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.